Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies

Neurology. 2003 Jun 10;60(11):1852-3. doi: 10.1212/01.wnl.0000068336.84399.9e.


Butyrylcholinesterase is implicated in the pathology of AD. Selective inhibitors increase acetylcholine and improve cognitive function in animal models. In dementia with Lewy bodies, cholinergic activities are more affected than in AD. The authors report a highly significant association between temporal cortex butyrylcholinesterase activity and the rate of cognitive decline in a prospectively studied, autopsy-confirmed dementia with Lewy bodies series.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Butyrylcholinesterase / metabolism*
  • Cognition Disorders / diagnosis*
  • Cognition Disorders / enzymology
  • Disease Progression
  • Female
  • Humans
  • Lewy Body Disease / diagnosis*
  • Lewy Body Disease / enzymology
  • Male
  • Prospective Studies
  • Temporal Lobe / enzymology


  • Butyrylcholinesterase